SCHEMBL12198179

SCHEMBL12198179

Nc1nc(O)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 14/20 0.78
PIK3CA P42336 2/20 0.78
PIK3CB P42338 2/20 0.78
PIK3CD O00329 1/20 0.78
PIK3C2B O00750 1/20 0.78
PDXK O00764 1/20 0.78
GAK O14976 1/20 0.78
MAP3K7 O43318 1/20 0.78
RIPK2 O43353 1/20 0.78
PIP5K1C O60331 1/20 0.78
STK16 O75716 1/20 0.78
PIK3C2G O75747 1/20 0.78
PRKD3 O94806 1/20 0.78
OXSR1 O95747 1/20 0.78
LATS1 O95835 1/20 0.78
ABL1 P00519 1/20 0.78
EGFR P00533 1/20 0.78
ERBB2 P04626 1/20 0.78
LCK P06239 1/20 0.78
BRAF P15056 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tg100-115 SCHEMBL29411790 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL29361550 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL31238338 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL360279 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL29369340 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL29506727 0.88 PIK3CG (1.00) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL3539255 0.87 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL3539251 0.87 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
Tg100-115 SCHEMBL3537211 0.87 PIK3CG (0.97) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B
SCHEMBL3532507 0.84 PIK3CG (0.60) PIK3CGPIK3CAPIK3CBPIK3CDPIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS AQP3, AQP1, AQP4 PIK3CG 1473/4885PIK3CA 799/4885PIK3CB 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.